secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001802768-26-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Royalty Pharma Reports Q4 and Full Year 2025 Results; Portfolio Receipts Up 18% and 16% Respectively
--------------------------------------------------------------------------------

- Portfolio Receipts reached $874M in Q4 2025 (up 18%) and $3,254M for FY 2025 (up 16%).
- Net cash from operating activities was $827M in Q4 and $2,490M for FY 2025.
- Deployed $2.6B in capital on royalty transactions in 2025, including nine new therapies.
- Repurchased 37M shares for $1.2B and increased quarterly dividend by 7% to $0.235.
- Provided FY 2026 guidance: Portfolio Receipts expected between $3,275M and $3,425M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276826000002/0001802768-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276826000002/rprx-20260211.htm
  HTML page:      https://secwatch.observer/filing/0001802768-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer